Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYRAMZA vs DAUNOXOME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II activity and preventing DNA replication and transcription. Liposomal encapsulation (Dauno Xome) alters distribution, reducing cardiotoxicity and enhancing tumor delivery.
Gastric or gastroesophageal junction adenocarcinoma, as monotherapy or with paclitaxel,Non-small cell lung cancer (NSCLC), in combination with docetaxel,Metastatic colorectal cancer, in combination with FOLFIRI,Hepatocellular carcinoma (HCC), as monotherapy,Off-label: Advanced urothelial carcinoma, endometrial cancer
Treatment of advanced HIV-associated Kaposi sarcoma as first-line therapy,Acute myeloid leukemia (off-label),Acute lymphoblastic leukemia (off-label)
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
60-80 mg/m² intravenously over 1 hour every 2-4 weeks.
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Terminal elimination half-life is approximately 30-40 hours (range 20-48 h); prolonged compared to conventional doxorubicin due to liposomal encapsulation, allowing extended drug exposure.
Ramucirumab is a monoclonal antibody; metabolism is via catabolism into small peptides and amino acids (nonspecific proteolytic degradation). No major metabolic enzymes involved.
Primarily hepatically metabolized via reduction to daunorubicinol by cytoplasmic reductases, and additionally by aldo-keto reductases and NADPH-dependent enzymes. Excretion: biliary and renal.
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Primarily biliary/fecal (40-50% as unchanged drug and metabolites); renal excretion accounts for approximately 5-15% as unchanged drug and metabolites over 5 days.
Approximately 95% bound to serum proteins, primarily albumin and immunoglobulins.
Approximately 90-95% bound, primarily to plasma proteins (albumin); minimal displacement interactions reported.
Volume of distribution at steady state is approximately 5.0–6.0 L, corresponding to 0.07–0.09 L/kg (assuming 70 kg body weight), indicating limited extravascular distribution primarily within plasma volume.
Vd is approximately 2-3 L/kg, indicating extensive tissue distribution; liposomal formulation concentrates in RES organs (liver, spleen) and tumors with leaky vasculature.
Bioavailability is 100% as ramucirumab is administered only by intravenous infusion; no oral or other form is available.
Only administered intravenously; oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and instability in GI tract.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment or dialysis.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) and consider dose reduction.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, no dosing information available; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or avoid use.
Safety and efficacy not established in pediatric patients.
60-80 mg/m² intravenously over 1 hour every 2-4 weeks; safety and efficacy not established in children under 2 years.
No dose adjustment required based on age. Monitor for increased risk of adverse events such as hypertension, hemorrhage, and gastrointestinal perforations.
No specific dose adjustment; monitor for increased toxicity due to age-related organ dysfunction.
Hemorrhage: Severe or fatal hemorrhage, including gastrointestinal hemorrhage, hemoptysis, and intracranial hemorrhage, has occurred. Do not administer in patients with severe bleeding.
Dauno Xome should be administered under the supervision of a physician experienced in cancer chemotherapy. Severe myelosuppression occurs. Cardiac toxicity, including potentially irreversible cardiomyopathy, may occur, especially with cumulative doses >600 mg/m². Extravasation can cause severe tissue necrosis.
Hemorrhage risk: Serious and sometimes fatal hemorrhagic events; permanently discontinue if severe bleeding occurs.,Arterial thromboembolic events: Including myocardial infarction and stroke; discontinue if occurs.,Gastrointestinal perforation: Fatal cases reported; discontinue if occurs.,Impaired wound healing: Interrupt therapy 28 days prior to elective surgery; do not resume until wound fully healed.,Hypertension: Monitor blood pressure; treat with antihypertensives; temporarily withhold if severe hypertension occurs.,Proteinuria: Monitor urine protein; withhold for >2 g/24h; discontinue if nephrotic syndrome develops.,Hypersensitivity/infusion reactions: Permanently discontinue if severe reaction occurs.,Thyroid dysfunction: Monitor thyroid function during treatment.
Monitor cardiac function (LVEF) regularly; cumulative dose limit 600 mg/m². Monitor blood counts for myelosuppression. Infusion reactions (hypotension, dyspnea) may occur. Not interchangeable with conventional daunorubicin.
Severe hemorrhage (active bleeding),Hypersensitivity to ramucirumab or any excipients
Hypersensitivity to daunorubicin or any component of Dauno Xome. Severe hepatic impairment. Severe, pre-existing myelosuppression. Pregnancy (category D).
No specific food interactions are documented. Avoid grapefruit juice if taking concomitant drugs metabolized by CYP3A4 (e.g., simvastatin) due to potential interaction, but no direct interaction with ramucirumab.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition altering drug metabolism. No other significant food interactions. Maintain adequate hydration to prevent tumor lysis syndrome.
Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal reproduction studies, intravenous administration of ramucirumab to pregnant rabbits during organogenesis resulted in embryofetal mortality and reduced fetal weight at exposures less than the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Cyramza is contraindicated in pregnancy. First trimester: High risk of teratogenicity; VEGF inhibition interferes with embryonic vascular development. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and potential for fetal renal impairment due to anti-angiogenic effects. Avoid use during pregnancy.
Daunorubicin (Dauno Xome) is teratogenic in animal studies. First trimester: Avoid; major congenital malformations (cardiac, skeletal) reported. Second/third trimester: Use only if benefit outweighs risk; risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Fetal toxicity is dose-dependent.
No human data available on the presence of ramucirumab in human milk, effects on the breastfed infant, or effects on milk production. Ramucirumab is a large protein molecule (Ig G1 monoclonal antibody) and is likely to be present in breast milk at low levels, especially in early postpartum period. However, because of the potential for serious adverse reactions in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 months after the last dose. M/P ratio: Not determined.
Contraindicated during breastfeeding. Daunorubicin is excreted into human milk; M/P ratio not available. Potential for severe adverse reactions (immunosuppression, neutropenia, carcinogenesis) in the nursing infant. Advise to discontinue breastfeeding for at least 7-10 days after last dose.
Cyramza is contraindicated in pregnancy; no dosing adjustments are recommended as use should be avoided. If used inadvertently, no specific pharmacokinetic data in pregnancy are available; however, physiological changes (e.g., increased plasma volume, altered renal function) may affect drug clearance, but no dose adjustment guidelines exist. The risk of fetal harm outweighs any potential benefit, and treatment should be discontinued immediately if pregnancy occurs.
No established dosing guidelines. Use lowest effective dose with standard body surface area calculations. Increased volume of distribution in pregnancy may require dose increase, but lack of safety data. Monitor for enhanced toxicity; consider dose reduction if severe myelosuppression or cardiotoxicity occurs.
CYRAMZA (ramucirumab) is a VEGFR-2 antagonist; premedicate with antihistamines and acetaminophen before infusion to reduce infusion-related reactions. Monitor blood pressure closely as hypertension is common; hold for severe hypertension. Avoid use in patients with significant bleeding risk or recent thromboembolic events. Do not administer with platinum-based chemotherapy in NSCLC patients with EGFR or ALK mutations unless progression on targeted therapy.
Dauno Xome (liposomal daunorubicin) has reduced cardiotoxicity compared to conventional daunorubicin due to preferential uptake by reticuloendothelial system. Cumulative lifetime dose limit is 600-800 mg/m² in adults (higher than conventional daunorubicin). Monitor for infusion reactions (flushing, dyspnea) especially during first dose. Myelosuppression is dose-limiting. Premedicate with antiemetics. Not interchangeable with conventional daunorubicin on mg/m² basis.
You may experience high blood pressure; monitor regularly and report symptoms like severe headache or vision changes.,This drug can increase bleeding risk; inform your doctor if you have any unusual bruising or bleeding.,Infusion reactions may occur; you will receive premedication to reduce this risk.,Report any new or worsening shortness of breath, chest pain, or leg swelling as these could be signs of blood clots or heart problems.,Wound healing may be impaired; avoid elective surgery during treatment and inform all healthcare providers you are on this medication.,Effective contraception is required during treatment and for at least 3 months after final dose.
This medication may cause temporary hair loss, nausea, vomiting, and mouth sores.,Report any signs of infection (fever, chills) or unusual bleeding/bruising immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 6 months after last dose.,Do not receive live vaccines during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYRAMZA vs DAUNOXOME, answered by our medical review team.
CYRAMZA is a Antineoplastic Monoclonal Antibody that works by Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.. DAUNOXOME is a Anthracycline Antineoplastic that works by Daunorubicin intercalates between DNA base pairs, inhibiting topoisomerase II activity and preventing DNA replication and transcription. Liposomal encapsulation (Dauno Xome) alters distribution, reducing cardiotoxicity and enhancing tumor delivery.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYRAMZA and DAUNOXOME depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYRAMZA is: 8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.. The standard adult dose of DAUNOXOME is: 60-80 mg/m² intravenously over 1 hour every 2-4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYRAMZA and DAUNOXOME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYRAMZA is classified as Category C. Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal rep. DAUNOXOME is classified as Category C. Daunorubicin (DaunoXome) is teratogenic in animal studies. First trimester: Avoid; major congenital malformations (cardiac, skeletal) reported. Second/third trimester: Use only if . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.